In summary, the ability of the 4E-BP1 mutant to phenocopy the effect of TOR-KI demonstrates that targeting the 4E-BP1/eIF4E arm of mTORC1 signalling is a promising approach for sensitisation of DLBCL cells to venetoclax treatment. Here, EIF4E is linked to diffuse large B-cell lymphoma.